A 32-year-old woman from Mumbai with a 5-year history of secondary infertility and irregular cycles (35–45 days) presents for ovulation induction. Her BMI is 28 kg/m². Pelvic ultrasound reveals multiple small follicles in both ovaries (>12 follicles of 2–8 mm per ovary) with increased ovarian stroma. Serum FSH is 6.5 mIU/mL, LH 18 mIU/mL, and testosterone 0.8 ng/mL (elevated). Free androgen index is 4.2 (elevated). She is diagnosed with polycystic ovary syndrome (PCOS). After 3 months of lifestyle modification and metformin 1500 mg daily, she still has irregular cycles. She is now started on clomiphene citrate 50 mg daily from day 3 to day 7. On day 12, ultrasound shows 4 follicles measuring 16–18 mm, 14 mm, 12 mm, and 10 mm. Endometrial thickness is 9 mm. What is the most appropriate next step?

Explanation

## Clinical Context: PCOS and Ovulation Induction with Clomiphene Citrate **Key Point:** In a PCOS patient on clomiphene citrate with multifollicular development, the management decision hinges on the number and size of mature (≥14 mm) follicles and the risk of multiple gestation/OHSS. ## Follicular Assessment on Day 12 | Follicle Size | Status | Clinical Significance | |--------------|--------|----------------------| | 16–18 mm | Dominant, near-mature | Will ovulate with hCG trigger | | 14 mm | Approaching maturity | May co-ovulate | | 12 mm | Intermediate | Less likely to ovulate | | 10 mm | Small | Unlikely to ovulate | | Endometrium | 9 mm | Adequate (>7 mm = receptive) | ## Why hCG Trigger + Timed Intercourse (Option C) Is Most Appropriate 1. **Number of truly mature follicles is acceptable:** Only 1–2 follicles are at or near the mature threshold (≥14 mm). ASRM and RCOG guidelines recommend cycle cancellation when **≥3 follicles ≥14 mm** are present. This patient has at most 2 follicles at or near that threshold (16–18 mm and 14 mm), making timed intercourse with hCG trigger a safe and standard approach. 2. **hCG 5000 IU trigger:** Standard dose for clomiphene cycles. Triggers final oocyte maturation and ovulation ~36 hours post-injection, allowing precise timing of intercourse. 3. **No indication for IUI (Option A):** IUI is indicated when there is a documented male factor, cervical factor, or prior failed timed intercourse cycles — none of which are established in this stem. Adding IUI without such indications is not supported by ASRM or RCOG guidelines and does not reduce OHSS risk. 4. **Endometrial thickness of 9 mm** is excellent for implantation (optimal >8 mm). ## Why Not the Other Options? - **Option A (hCG + IUI):** IUI is not indicated without male factor or cervical factor. The stem provides no evidence of either. Timed intercourse is the standard first-line approach in clomiphene cycles with 1–2 dominant follicles per ASRM guidelines and Dutta's Textbook of Gynecology. - **Option B (Continue clomiphene 2 more days):** Unnecessary. The lead follicle is already 16–18 mm and ready for triggering. Continuing clomiphene risks over-maturation and luteinization without ovulation. - **Option D (Cancel cycle, switch to letrozole):** Premature and overly conservative. Cancellation is reserved for ≥3 follicles ≥14 mm with very high OHSS/multiple gestation risk. This patient has only 1–2 truly mature follicles, and OHSS risk is not prohibitive. **Clinical Pearl:** Per ASRM Practice Committee guidelines and Dutta's Textbook of Gynecology, hCG trigger followed by timed intercourse is the standard of care in clomiphene cycles with 1–2 dominant follicles (≥18 mm). IUI is reserved for cycles with documented male or cervical factor infertility. **High-Yield:** Cycle cancellation threshold in clomiphene/gonadotropin cycles = **≥3 follicles ≥14 mm** (RCOG/ASRM). Below this threshold, timed intercourse with hCG trigger is appropriate. [Cite: Dutta's Textbook of Gynecology, 8th ed., Ch. 16; ASRM Practice Committee: Use of clomiphene citrate in infertile women, Fertil Steril 2013]